RNU6-528P

Across TCGA pan-cancer cohorts, RNU6-528P RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RNU6-528P data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RNU6-528P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-528P expression acts as an unfavorable survival marker.

CHOL, PAAD, and THYM are the cancer types where RNU6-528P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Tertile	All	0.019	0.800	<.001	72	view →
PAAD	OS	Tertile	II,III,IV	0.273	0.561	.016	36	view →
THYM	OS	Tertile	All	0.352	0.884	<.001	24	view →
SARC	OS	Tertile	All	0.601	0.869	.006	21	view →
ESCA	OS	Tertile	II,III,IV	0.406	0.925	.037	18	view →
COAD	OS	Tertile	III,IV	0.168	0.691	.041	18	view →
ACC	OS	Tertile	All	0.146	0.622	.026	18	view →
BRCA	OS	Tertile	All	0.216	0.582	.014	12	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RNU6-528P–CHOL (OS)

Open the CHOL breakdown →